| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | JW-74 | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |